GlassScriptPhysician profile
Brian A Allee
NPI 1952340572
$3,080.78
in general payments reported to CMS, 2019-2025
26 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $329 · 2021: $689 · 2022: $240 · 2023: $242 · 2024: $428 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $814.49 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $473.56 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $377.87 | 2019-2025 | Rybelsus, Ozempic, Saxenda |
| Abbvie INC. | $373.90 | 2021-2025 | Vraylar |
| Sanofi-Aventis U.S. LLC | $174.69 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $124.60 | 2019-2021 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.27 | 2019-2021 | |
| Pfizer INC. | $85.33 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.47 | 2021-2023 | Jardiance |
| Exact Sciences Corporation | $61.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $48.97 | 2021-2022 | |
| Organon LLC | $35.14 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $29.90 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $28.63 | 2024-2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $24.19 | 2025 | Auvelity |
| Mylan Specialty L.P. | $23.54 | 2019 | |
| Edwards Lifesciences Corporation | $21.58 | 2024 | |
| Ironshore Pharmaceuticals INC. | $19.86 | 2019 | |
| Amgen INC. | $18.82 | 2025 | Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $15.21 | 2022 | |
| Sanofi Pasteur INC. | $14.61 | 2020 | |
| Dexcom, INC. | $13.33 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $13.02 | 2022 | |
| Allergan, INC. | $11.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Allee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.